Rhinomaris nasal spray 0.1% 15ml

Release form

Spray nasal 0.1% in the form of a transparent, transparent, odorless solution.

pharmachologic effect

Clinico-pharmacological group: Vasoconstrictor drug for local use in ENT practice

Pharmaco-therapeutic group: Anti-congestive agent - vasoconstrictor (alpha adrenomimetic)

pharmachologic effect

Vasoconstrictor drug for intranasal use. Xylometazoline has an alpha adrenomimetic effect: it causes constriction of the blood vessels of the nasal mucosa and thus eliminates the swelling and hyperemia of the nasopharyngeal mucosa. Relieves nasal breathing with rhinitis. In therapeutic concentrations does not irritate the mucous membrane, does not cause hyperemia.

The effect occurs a few minutes after application and lasts for 12 hours.

Sterilized seawater, which is part of the preparation Rhinomaris, helps to maintain the normal physiological state of the nasal mucosa, dilute mucus and normalize its production in the goblet cells of the nasal mucosa.

Trace elements improve the function of the ciliated epithelium, thereby reducing side local reactions, such as irritation and / or dryness of the nasopharyngeal mucosa.

Pharmacokinetics

When applied topically, the drug is practically not absorbed. The concentration of the active substance in the blood plasma is so small that it is impossible to determine them by modern analytical methods.

Indications

- acute respiratory diseases with rhinitis (rhinitis);

- allergic rhinitis (pollinosis);

- sinusitis;

- Eustachitis;

- otitis media (to reduce swelling of the mucous membrane of the nasopharynx);

- preparation of the patient for diagnostic manipulations in the nasal passages.

Contraindications

- arterial hypertension;

- tachycardia;

- pronounced atherosclerosis;

- glaucoma;

- atrophic rhinitis;

- thyrotoxicosis;

- Surgery on the meninges (in history);

- children's age up to 6 years (for a nasal spray of 0.1%);

- children's age up to 2 years (for a nasal spray 0.05%);

- hypersensitivity to the drug.

With caution should use the drug for diabetes, coronary artery disease.

Use during pregnancy and lactation

In pregnancy and lactation (breastfeeding), the drug should be used only after a careful assessment of the risk-benefit ratio for the mother and the fetus or infant. Do not exceed the recommended doses.

special instructions

Before use, you must clean the nasal passages.

Rhinomaris should not be used for a long time, for example, in chronic rhinitis.

Influence on ability to drive motor transport and control mechanisms

Xylometazoline in doses higher than those recommended may affect the ability to drive a vehicle or equipment.

Composition

Xylometazoline hydrochloride 10 mg

Excipients: water of the Adriatic Sea - 2.4162 g, potassium dihydrogen phosphate - 4.9 mg, purified water - up to 10 ml.

Dosage and administration

Rhinomaris nasal spray dosed with 0.05%

Children aged 2 to 6 years: 1 injection in each nostril 1-2 times / day.

Children older than 6 years: 1 injection in each nostril 2-3 times / day.

Renomaris nasal spray dosed 0.1%

Children over 6 years old and adults: 1 injection in each nostril 2-3 times / day.

The drug should not be used more often 4 times a day. Course duration - no more than 5-7 days.

Side effects

On the part of the respiratory system: with frequent and / or long-term use - irritation and / or dryness of the nasopharyngeal mucosa, burning, tingling, sneezing, hypersecretion, swelling of the nasal mucosa.

Cardiovascular: palpitations, tachycardia, arrhythmias, increased blood pressure.

From the nervous system: headache, insomnia; with prolonged use in high doses - depression.

Other: vomiting, blurred vision.

Drug interaction

Renomarie is incompatible with MAO inhibitors and tricyclic antidepressants.

Overdosage

Symptoms: increased side effects.

Treatment: symptomatic treatment.

Storage conditions

The drug should be stored out of reach of children at a temperature not exceeding 25 ° C.